IL22 and graft versus host disease: In murine models of acute GvHD, treatment with recombinant IL-22 increased the number of stem cells, improved epithelial integrity, enhanced the expression of antimicrobial peptides such as Reg3β and Reg3γ; and finally resulted in reduced mortality (11, 12).